Irritable Bowel Syndrome Treatment Market Rise in research & development activities for the development of irritable bowel syndrome drugs are expected to drive the market growth | Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc

Overview:

Irritable bowel syndrome treatment majorly involves relieving patients from symptoms related to the condition as the reasons why the disease occurs are still not known. The symptoms of the disease include constipation, diarrhea, and abdominal pain. If these symptoms are long term and recurring, it indicates the possibility of the syndrome. The treatments available for irritable bowel syndrome depend on how severe these symptoms are that are characterized as severe, moderate and mild.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/506

Market Drivers:

Rise in distribution agreements in market players is expected to augment growth of the global irritable bowel syndrome treatment market over the forecast period. For instance, in May 2022, a leading developer and market innovator, Biome Australia Limited entered into a distribution agreement with Australian Pharmaceutical Industries Limited for selling its core range of activated probiotics in 370 pharmacies which took its distribution footprint to nearly 3,000 stores in Australia.

Furthermore, market players are increasingly adopting growth strategies such as acquisition and this in turn is projected to boost growth of the global irritable bowel syndrome treatment market over the forecast period. For instance, in February 2019, a leading company, Bausch Health Companies, Inc. acquired specific assets of Synergy Pharma, a leading pharmaceutical firm and its product TRULANCE, a tablet for adults with chronic idiopathic constipation and irritable bowel syndrome.

Impact of COVId-19:

The epidemic of COVID-19 lucratively impacted some of the industries. It positively impacted the global irritable bowel syndrome treatment market as the disease had possible relation to COVID-19 infection. As per an article published in the National Center for Biotechnology Information in November 2021, individuals with COVID-19 infection can exhibit imbalance in gut microbiota, which indicates that dysregulation of gut-microbiota induced by COVID-19 could improve predisposing circumstances for IBS. Hence, the market in discussion witnessed positive impact of the COVID-19 pandemic.

Regional Analysis:

North America is anticipated to witness robust growth in the global irritable bowel syndrome treatment market during the forecast period. This is due to rise in net sales of drugs for irritable bowel syndrome across the region. For instance, a healthcare company Ironwood Pharmaceuticals, Inc. received brand status with more than US$ 1 billion in the 2021 net sales in the U.S. for LINZESS, a novel drug for patients suffering irritable bowel syndrome with constipation.

Key Takeaways:

• The global irritable bowel syndrome treatment market is estimated to have a CAGR of 13.2% over the forecast period, owing to rise in adoption of various inorganic growth strategies by market players. For instance, in September 2019, Ironwood Pharmaceuticals Inc. entered into an agreement with AstraZeneca for the development, manufacturing as well as marketing of LINZESS, a drug for irritable bowel syndrome in China.
• The Hospital Pharmacies segment among Distribution Channel is likely to witness strong growth in the global irritable bowel syndrome treatment market due to rise in number of irritable bowel syndrome cases. For instance, an article published in the National Center For Biotechnology Information in May 2018, reported that nearly 7% to 16% of population in the U.S. is likely to be affected by irritable bowel syndrome.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/506

Key Players

Key players active in the global irritable bowel syndrome treatment market are Takeda Pharmaceutical Company Limited, Abbott, Ironwood Pharmaceuticals, Inc., Synergy Pharma, GSK plc., Mallinckrodt, Novartis AG, Bausch Health Companies Inc., Astellas Pharma Inc., and Ardelyx.

Key Developments:

March 2022: metaMe Health, Inc. received US$ 2.2 Mn funding in a bridge round that Hyde Park Angels led with extra investments from individuals.

August 2021: Dr. Reddy’s Laboratories Ltd. launched chlorodiazepoxide hydrochloride and clidinium bromide capsules USP, 5mg/2.5 mg used for treatment of peptic ulcer, acute enterocolitis and irritable bowel syndrome as an adjunctive therapy.

Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/506

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Irritable Bowel Syndrome Treatment Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Irritable Bowel Syndrome Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Irritable Bowel Syndrome Treatment Industry Impact

Chapter 2 Global Irritable Bowel Syndrome Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Irritable Bowel Syndrome Treatment (Volume and Value) by Type
2.3 Global Irritable Bowel Syndrome Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Irritable Bowel Syndrome Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Irritable Bowel Syndrome Treatment Market Analysis
Chapter 6 East Asia Irritable Bowel Syndrome Treatment Market Analysis
Chapter 7 Europe Irritable Bowel Syndrome Treatment Market Analysis
Chapter 8 South Asia Irritable Bowel Syndrome Treatment Market Analysis
Chapter 9 Southeast Asia Irritable Bowel Syndrome Treatment Market Analysis
Chapter 10 Middle East Irritable Bowel Syndrome Treatment Market Analysis
Chapter 11 Africa Irritable Bowel Syndrome Treatment Market Analysis
Chapter 12 Oceania Irritable Bowel Syndrome Treatment Market Analysis
Chapter 13 South America Irritable Bowel Syndrome Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Irritable Bowel Syndrome Treatment Business
Chapter 15 Global Irritable Bowel Syndrome Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology